Dr. Bryan Ardis - Vaping

VARENICLINE FOR YOUTH NICOTINE VAPING CESSATION: A RANDOMIZED CLINICAL TRIAL

Electronic cigarette use (vaping) among adolescents and young adults is common. Few treatments have been tested in this population.  In this 12-week randomized clinical trial in 261 treatment-seeking youth, aged 16 to 25 years, continuous abstinence rates in the last month of treatment (51% vs 14%) and at 6-month follow-up (28% vs 7%) were higher in the varenicline group than in the placebo group. Treatment-emergent adverse events did not differ significantly between groups.  Varenicline, when added to brief cessation counseling, is well tolerated and promotes nicotine vaping cessation compared with placebo in youth with addiction to vaped nicotine.   Participants were randomized (1:1:1) to 12 weeks of varenicline titrated to 1 mg twice daily over 7 days (standard titration), weekly counseling, and referral to text messaging vaping cessation support (This is Quitting [TIQ]) (n = 88); identical placebo, weekly counseling, and referral to TIQ (n = 87); or enhanced usual care (referral to TIQ only) (n = 86).

Is varenicline, when added to brief, remotely delivered behavioral support, efficacious and well tolerated for nicotine vaping cessation in youth?

A healthcare whistleblower and the author of the bestselling book "Moving Beyond the Covid-19 Lies: Restoring Health and Hope for Humanity" DR. BRYAN ARDIS